Project Grant R21AR086358
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,829,773 project grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Florida. The grant, awarded on September 5, 2025, will fund research to investigate the mechanisms by which sepsis harms muscles and impedes proper regeneration, with the goal of developing new strategies to improve septic patients' recovery of skeletal muscle function...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $439,791 Project Grant to The University of Texas Southwestern Medical Center on March 1, 2025 under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846). The grant supports research to investigate the molecular mechanisms of myoblast fusion, which is essential for skeletal muscle development and regeneration. The research aims to understand the cellular and...
- This $820,142 Project Grant was awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research (CFDA 93.846) program. The grant aims to investigate the effects of early-life physical inactivity in mice on muscle quality, function, and frailty development in adulthood. Specifically, the research will examine the regulatory aspects of the extracellular matrix, muscle macrophages, and physical...
- This Project Grant award of $522,714 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the role of stretch activation in mammalian skeletal muscle endurance. The research will focus on measuring the characteristics and mechanisms of stretch activation in mouse slow-twitch and fast-twitch muscle fibers, including determining the specific myosin...
- This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $352,777 to support research into the regulation of sarcomere growth in skeletal muscle. The research aims to: 1) Identify molecular targets that impact sarcomere addition during muscle growth, and 2) Use in vivo protein tagging methods to study the dynamics of newly synthesized sarcomere...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is funding research on the role of HOX-expressing interstitial cells in muscle growth, homeostasis, and regeneration. The $557,357 award, effective from March 14, 2025 through February 28, 2030, will support a University of Wisconsin-Madison research project investigating the ability of a...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $554,797 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The University of Kentucky Research Foundation. This 5-year grant, awarded on September 1, 2025, will support research to define the rate of myonuclear turnover in adult skeletal muscles, identify the mechanisms by which myonuclei are degraded, and unravel the targeting complexes and cellular...
- This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the functional roles of microRNA-320 (miR-320) in skeletal muscle. The $374,204 award to The Leland Stanford Junior University will fully characterize a muscle-specific miR-320 knockout mouse model, examine the underlying mechanisms of the observed muscle wasting...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $216,113 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Weill Medical College of Cornell University. The grant funding will support research to target the GDF15-GFRAL signaling pathway to prevent and treat cachexia (muscle wasting) in a mouse model of mitochondrial myopathy. Specifically, the research aims to determine if inhibiting the GDF15-GFRAL...
- This $1,610,219 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846), will fund a 5-year longitudinal study examining the relationship between muscle quantity, quality, function, and biomarkers with changes in bone density, microarchitecture, and strength in older adults. The University of Pittsburgh will conduct this research, which aims to...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $198,263 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research federal grant program (CFDA 93.846) to the Board of Regents of the University of Nebraska. The research project aims to investigate the role of the protein Mitsugumin 53 (MG53) in preventing muscle atrophy during periods of disuse, which can contribute to age-related sarcopenia and frailty. The research will explore how elevated MG53 expression in hibernating mammals helps maintain muscle integrity and function, and test whether upregulation of MG53 and its associated pathways can mitigate disuse-induced muscle loss in a non-hibernating model system. The award period runs from September 5, 2025 to August 31, 2027.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $198.3k | 9/4/25 |